Clinical Trials Logo

Filter by:
NCT ID: NCT04807244 Not yet recruiting - Clinical trials for Irreversible Pulpitis

Treatment of Deep Carious Lesions With Selective Caries Removal, Partial or Full Pulpotomy

Vitapulp
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The optimal treatment of deep caries lesions extended to the inner third of dentin is still under discussion. Cariologists prefer selective caries removal, meanwhile endodontists recommend partial pulpotomy. So far, no clinical trial compared both interventions against each other. Additionally, current literature indicates alternative treatment options for irreversible pulpitis besides conventional orthograde root canal treatments like the partial or full pulpotomy. Existing clinical studies on this topic were using different clinical protocols, especially with regards to the accepted time to achieve hemostasis. It is still unclear, if the pulpal bleeding time prior to the capping procedure affects the outcome of partial or full pulpotomy.

NCT ID: NCT04807569 Not yet recruiting - Clinical trials for Bladder Hypersensitivity

The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The main hypothesis of this study is that peripheral magnetic neuromodulation can correct the symptoms of lower urinary tract in men. We assume that under the influence of t peripheral magnetic stimulation, both the subjective state of patients assessed by standardized questionnaires and a urination diary, as well as the objective parameters, assessed by non-invasive urodynamic studies, will be improved. This study will use standard protocols built into the BTL Emsella magnetic stimulator.

NCT ID: NCT04808895 Not yet recruiting - COVID-19 Clinical Trials

Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19

Asperum
Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

Inflammatory diseases favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended if concomitant inflammatory disease. In severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pneumonia an inflammation-dependent thrombotic process occurs and platelet activation may promote thrombosis and amplify inflammation, as indicated by previous experimental evidence, and the similarities with atherothrombosis and thrombotic microangiopathies. Antiplatelet agents represent the cornerstone in the prevention and treatment of atherosclerotic arterial thromboembolism, with limited efficacy in the context of venous thromboembolism. The use of acetylsalicylic acid may improve inflammation and respiratory function in humans as indicated by the results of observational studies. There are no validated protocols for thrombosis prevention in Covid-19. There is scientific rationale to consider acetylsalicylic acid for the prevention of thrombosis in the pulmonary circulation and attenuation of inflammation. This is supported by numerous demonstrations of the anti-inflammatory activity of antiplatelet agents and the evidence of improvement in respiratory function both in human and experimental pathology. The hypothesis underlying the present study project is that in Covid-19 platelet activation occurs through an inflammation-dependent mechanism and that early antithrombotic prophylaxis in non-critical patients could reduce the incidence of pulmonary thrombosis and respiratory and multi-organ failure improving clinical outcome in patients with SARS-CoV2 pneumonia. The prevention of thrombogenic platelet activity with acetylsalicylic acid could be superior to fixed dose enoxaparin alone. The proposed treatment is feasible in all coronavirus disease 2019 (COVID-19) patients, regardless of the treatment regimen (antivirals, anti-inflammatory drugs), except for specific contraindications. To this aim, the investigators a randomised, placebo-controlled, double blind, parallel arms study to investigate the potential protection of acetylsalicylic acid towards the progression of lung failure in patients admitted to a medical ward for SARS-CoV-2 pneumonia. A 15-day treatment period is considered. Primary endpoint is the occurrence of one of the following events: admission to an intensive care unit, requirement of mechanical ventilation, PaO2/FiO2 less than 150 mm Hg.

NCT ID: NCT04810663 Not yet recruiting - Clinical trials for Gastric Adenocarcinoma

Outcome of Radiation Therapy in Operated Gastric Cancer

Start date: April 1, 2021
Phase:
Study type: Observational

- Study tolerability and toxicity of radiotherapy with or without chemotherapy for operated gastric cancer. - Evaluate the efficacy of adjuvant radiotherapy with or without chemotherapy as regarding local control and overall survival.

NCT ID: NCT04812145 Not yet recruiting - Clinical trials for Urinary Bladder Cancer

Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma

Start date: April 1, 2021
Phase:
Study type: Observational

Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.

NCT ID: NCT04812236 Not yet recruiting - Metabolic Syndrome Clinical Trials

Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness

Start date: April 1, 2021
Phase: Phase 4
Study type: Interventional

In this study, a randomized, partially double-blind, controlled, multi-center clinical research method was used. A total of 4 groups were designed, namely, single decoction group, co-decoction group, powder group and simulation group. The four groups of patients all received basic health education, diet control and increased exercise guidance. All the patients in the group have taken western medicine according to their own conditions and followed the doctor's instructions for hypoglycemic, blood pressure, and lipid-lowering treatments. After joining the group, they continue to take the medicine at the original dose, and the patients are advised not to change the medicine during the observation period. Take 12 weeks as a course of treatment, and set the observation period to 12 weeks. Follow up every 4 weeks.

NCT ID: NCT04814069 Not yet recruiting - Clinical trials for Head and Neck Cancer

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinomaļ¼šThe POTENTIAL Study

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.

NCT ID: NCT04815148 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.

NCT ID: NCT04815265 Not yet recruiting - Sedation Clinical Trials

Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation

Start date: April 1, 2021
Phase: Phase 4
Study type: Interventional

Sedation is a component of the care of critically ill patients who are undergoing mechanical ventilation. Dexmedetomidine induces sedation while preserving a degree of arousability among patients in the intensive care unit (ICU), and its use has resulted in a shorter time to extubation, an increased number of days free from coma or delirium, a reduced incidence of agitated delirium, prevention of delirium, and lower mortality than other agents administered in certain populations. Hypotension and bradycardia are common side effects, which is lethal for the patients with persistent or severe hemodynamic instability. The pharmacological properties of rimazolom suggest that it is an ideal sedative drug for critically ill patients, but there is no relevant clinical research to confirm it. Therefore, this study mainly discusses the efficacy and safety of remidazolam in ICU patients with mechanical ventilation, so as to provide theoretical basis for individualized sedation treatment of patients with mechanical ventilation.

NCT ID: NCT04815655 Not yet recruiting - Clinical trials for Cartilage Tympanoplasty

Cartilage Tympanoplasty for Recurrent Perforation Full Thickness Versus Partial Thickness Graft

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Cartilage tympanoplasty for recurrent perforation full thickness versus partial thickness graft.